Home Stocks The Top 7 Private Equity Investors In Biotech

The Top 7 Private Equity Investors In Biotech

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

TA Associates has completed a growth investment in Aldevron, a biotech working to develop plasmid DNA, proteins and antibodies. Founded in 1998, the company makes biologics for research, clinical and diagnostic applications, including treatments for cancer, infectious disease and other disorders.

For private equity firms like TA Associates, the biotech and pharmaceuticals sector has been a source of stunningly consistent activity. In 2016, PE investors completed 113 deals in the space, according to the PitchBook Platform—the fourth time in the past five years that figure was somewhere between 110 and 114 (the outlier: 2014, when 126 biotech & pharma deals were done).

Which firms have been leading the way? Here are the top investors in the biotech and pharmaceuticals industry since the start of 2012, including add-ons:

1. TPG* (21)

2. RA Capital Management (17)

3. Ardian (16)

4. Warburg Pincus (10)

T-5. KKR (9)

T-5. Bain Capital (9)

7. Avista Capital Partners (8)

PitchBook users get the full list. Not a subscriber but interested in more PE data? Contact us today.

*Including deals by TPG Growth

Article by PitchBook

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.